Henrietta Ukwu, Executive Vice President and Chief Regulatory Officer
Professional Overview
Henrietta Ukwu is an accomplished pharmaceutical executive with over 30 years of experience in global regulatory affairs and quality assurance. As the Executive Vice President and Chief Regulatory Officer at NOVAVAX INC, she leverages her deep industry expertise to navigate complex regulatory landscapes and ensure the company's compliance with international standards.
Experience Summary
Current Role
As the Executive Vice President and Chief Regulatory Officer at NOVAVAX INC, Henrietta is responsible for overseeing the company's global regulatory strategy and quality management systems. She plays a pivotal role in securing approvals for NOVAVAX's innovative vaccine products, working closely with regulatory authorities worldwide to streamline the review and authorization processes.
Career Progression
Henrietta's distinguished career spans various leadership roles within the pharmaceutical industry. Prior to her current position, she served as the Senior Vice President, Chief Regulatory and Quality Officer at NOVAVAX INC, where she spearheaded the successful regulatory approval of the company's COVID-19 vaccine. Before that, she held senior regulatory affairs and quality management positions at Otsuka Pharmaceutical Companies (U.S.) and Pfizer Pharmaceuticals, demonstrating her ability to navigate complex regulatory environments and drive global quality initiatives.
Academic Background
Henrietta holds a Bachelor of Science degree in Pharmacy from the University of Nigeria, Nsukka. Her extensive industry knowledge and expertise have been recognized through her contributions to various industry associations and publications.
Areas of Expertise
- Global regulatory affairs and strategy
- Quality assurance and compliance management
- Vaccine development and approval processes
- Pharmaceutical industry leadership and team management
Professional Impact
Throughout her career, Henrietta has been instrumental in the successful regulatory approval and commercialization of numerous pharmaceutical products, including vaccines. Her strategic guidance and collaborative approach have earned her a reputation as a trusted industry leader, and her contributions have positively impacted patient access to innovative healthcare solutions.
Conclusion
With her deep understanding of the regulatory landscape and a proven track record of driving quality and compliance initiatives, Henrietta Ukwu is well-positioned to continue advancing NOVAVAX's mission of developing and delivering transformative vaccine solutions that address global health challenges.
